Novartis Taps Biosimilar Experience in Europe to Snag U.S. Sales

  • Drugmaker to launch competitor to Amgen’s blockbuster Enbrel
  • Novartis plans copies of live drugs worth $44 billion in sales

Novartis AG, which just won U.S. approval for a lower-priced version of Amgen Inc.’s blockbuster arthritis drug Enbrel, estimates that the market for copies of biotechnology drugs could grow seven-fold by the end of the decade.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.